AKTX 8-K: SEC filing

Filed with the SEC on Nov 12, 2026 · accession 0001493152-26-051486

AKTX filed a 8-K (current report) with the SEC on Nov 12, 2026. Akari Therapeutics furnished a press release announcing its financial results for the third quarter ended December 31, 2026.

Summary of the filing

Akari Therapeutics furnished a press release announcing its financial results for the third quarter ended December 31, 2026. The filing is an Item 2.02 earnings release furnished under Form 8-K.

For details, click here →How to read a 8-K →

Key details

RegistrantAkari Therapeutics, Plc

Interim chief financial officerKameel Farag

✦ Ask GOAX AI about this filing — what it means for AKTX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for AKTX?

Click here

Frequently asked questions

What did AKTX file with the SEC on Nov 12, 2026?

AKTX filed a 8-K (SEC filing). Akari Therapeutics furnished a press release announcing its financial results for the third quarter ended December 31, 2026. The filing is an Item 2.02 earnings release furnished under Form 8-K.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other AKTX SEC filings

Get alerts when AKTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

AKTX overview AKTX analysis AKTX news Latest SEC filings